Sandoz Canada completes its 5th biosimilar launch with new biosimilar Hyrimoz® (adalimumab)

NEXT STORY
Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2021 and Provides Corporate Update
PREV STORY
Herbal Medicine Market Global Sales Are Expected To Reach US$ 550 Billion by 2030, as stated by insightSLICE
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Sanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis

Sanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in Patients With ...

author_avatar
NASDAQ Market News

Cytokinetics Names Robert Califf, M.D., to Board of Directors

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced ...

author_avatar
NASDAQ Market News

Ritter Pharmaceuticals, Inc. Prices $23,000,000 Public Offering

Los Angeles, California, Sept. 29, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ...

author_avatar
NASDAQ Market News